PDCD1 and neoplasm: Tumor expression of VISTA increases after anti-PD-1 or anti-CTLA-4 treatment (7, 8); for example, 43% of patients treated with anti-PD-1 monotherapy relapsed within 3 years due to acquired resistance with high VISTA tumor expression (9).